Why so many COVID-19 clients get blood clots (apoplexy) remains unsure. However scientists at Uppsala University and the University Medical facility have now determined a mechanism they think to be implicated. A particular protein triggers a part of our immune system that can increase the blood’s tendency to coagulate and form clots. The study is now published in Thrombosis and Haemostasis
Because thrombosis has shown to be a typical problem in serious COVID-19, many people getting medical facility look after the disease get them.
In a new study, researchers at Uppsala University have actually discovered that a key mechanism of embolisms formation in COVID-19 may be activation of what is called the complement system, which belongs to the body immune system we are born with. This can be initiated by particular proteins, one example being mannose-binding lectin (MBL).
Sixty-five clients getting intensive care at Uppsala University Hospital had their MBL levels and activity determined. In all those who established thrombosis throughout their healthcare facility stay, MBL activity and levels were discovered to be raised.
The study suggests that the enhance system not only is consisted of in our immune defences, however can likewise serve to increase the blood’s thickening tendency.
” Our outcomes are especially intriguing since we believe MBL activates blood coagulation in such a way that blood-thinning drugs can’t avoid. This might explain why so many clients struggle with embolisms in spite of treatment,” says the research study’s lead author Oskar Eriksson, a doctor at the University Health center and scientist at the Department of Immunology, Genes and Pathology, Uppsala University.
The scientists believe their results may eventually result in testing of MBL activity in COVID-19 patients to recognize those who are at high threat of getting apoplexy. MBL might also be a possible target in future development of drugs to prevent the condition.